Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bayer AG

Bristol-Myers

British American Tobacco

Imperial Brands PLC

Intel

Merck

Roche Holding AG

Western Union

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).

Wide-Moat Stocks On Sale - The December 2021 Heat Map

Baidu

Baidu Inc (NASDAQ: BIDU) has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA (NASDAQ: SNY) for use in designing vaccine and therapeutic products. The deal marks Baidu's first such commercial deal with a major global drugmaker.

Baidu Licenses Its Algorithm To Sanofi For mRNA Vaccine, Therapy Development

Chinese tech giant Baidu Inc said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.

Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development

AbbVie

Inovio Pharmaceuticals

Novavax

Pfizer

Could these top biotech stocks be worth investing in for the long term?

5 Biotech Stocks To Check Out In The Stock Market Now

Vici Properties

Vodafone Group

Actually, investors can have their cake and eat it too, balancing current income with principal appreciation.

These 3 High-Yield Dividend Stocks Are Growing at Blazing Speeds

Drugmaker Sanofi is investing $180 million in French startup Owkin, whose predictive algorithms aim to improve the research and development of new cures against cancer, the Paris-based group said on Thursday.

Drugmaker Sanofi invests $180 million in French AI startup Owkin

Sanofi invests $180 million equity in Owkin's artificial intelligence and federated learning to advance oncology pipeline

Kadmon Hlds

Sanofi completes acquisition of Kadmon

ABVC BioPharma

ANI Pharma

Moderna

Sorrento Therapeutics Inc

Biotech stocks to note as the coronavirus pandemic rages on across the globe.

Best Biotech Stocks To Buy Now? 5 To Check Out In November 2021

Sanofi (SNY) CEO Paul Hudson on Q3 2021 Results - Earnings Call Transcript

Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It raises earnings growth guidance range for the year.

Sanofi (SNY) Q3 Earnings Beat, Sales Miss, 2021 EPS View Up

French drugmaker Sanofi again raised its profit guidance for 2021 as its blockbuster eczema drug Dupixent and flu vaccines helped it beat market forecasts in the third quarter.

Drugmaker Sanofi raises 2021 profit guidance again after Q3 beat

Sanofi : Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1)

Donegal Group

FS KKR Capital Corp

Golub Capital BDC

Gold Fields Ltd.

Kenon Hlds

China Life Insurance Co. Ltd.

Owl Rock Capital Corp

POSCO

Qiwi

Rio Tinto plc Sponsored

Sibanye Stillwater

Companhia Siderurgica Nacional

Vale S.A.

"Benjamin Graham Value Stocks match the criteria Benjamin Graham followed." - YCharts Value Screener. 35 Graham formula picks screened by YCharts October 8, 2021 are based on Graham's established criteria. Of those, 26 matched the dogcatcher ideal dividend from $1K invested exceeding single share price.

Benjamin Graham's Formula Nails 26 Top Value Dividend Winners For October

If history is any guide, there may be trouble ahead for shares of Sanofi(NASDAQ:SNY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Will Chart Analysts Notice Bad Omen on Sanofi's Chart

U.S.-listed shares of Sanofi SNY, +0.37% gained 0.4% in trading on Friday after it announced that co-administering a flu shot with Moderna Inc.'s MRNA, -3.33% experimental COVID-19 booster in seniors is safe and effective. Moderna's stock was down 2.7%.

Giving Moderna's COVID-19 booster at the same time as Sanofi's flu is safe and effective

AstraZeneca

Gilead Sciences

GlaxoSmithKline

Johnson & Johnson

Eli Lilly

Large-cap pharmaceutical stocks offer investors stable, substantial dividends, regardless of market conditions. Here are nine that stand out.

9 Big Pharmaceutical Stocks Sporting Stellar Yields

Three healthcare giants are vying for the prize.

After COVID-19, Could This Be the Next Billion-Dollar Vaccine Market?

BioNTech SE

Novo Nordisk

Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.

3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health

Sanofi (SNY) dumps development of mRNA-based COVID vaccine despite promising data from an early study. Instead, it will focus on its adjuvanted recombinant protein vaccine candidate.

Sanofi (SNY) Ends mRNA COVID Vaccine Bid Despite Positive Data

Sanofi SA (NASDAQA:SNY) announced that it will be suspending any further developments of its mRNA-based Covid-19 vaccine, despite positive results in its last study, as inoculations from Moderna (MRNA) and Pfizer (PFE) dominate the market.

Sanofi Suspends mRNA Vaccine Development Amid Stiff Competition

The French pharma giant continues work on a recombinant Covid-19 vaccine with GlaxoSmithKline, which is also being evaluated as a booster shot.

A Sanofi Covid Vaccine Had Positive Early Trials. Why Is It Being Shelved?

Sanofi SA (NASDAQ: SNY) is dropping plans for its mRNA-based COVID-19 vaccine because it believes it will be too late in reaching the market, STAT news reported. Sanofi says that the market is well-served with the dominant role of BioNTech SE (NASDAQ: BNTX) - Pfizer Inc (NYSE: PFE) alliance and Moderna Inc (NASDAQ: MRNA).

Sanofi Stops Work On Its mRNA COVID-19 Vaccine: What You Need To Know

Sanofi Halts Development of Its mRNA Covid-19 Vaccine. The Stock Is Rising.

Vertex Pharmaceuticals

Analysts expect one of them could skyrocket more than 40% over the next 12 months.

News for Sanofi Stock (SNY)